Heart rate control in chronic heart failure patients received cardiovascular implantable electronic device therapy: effects of optimized medication
10.3760/cma.j.issn.0253-3758.2018.03.002
- VernacularTitle: 接受心血管植入型电子器械治疗的心力衰竭患者术后心率管理的研究
- Author:
Yang GAO
1
;
Yanchun LIANG
;
Haibo YU
;
Xiaolei YAN
;
Baige XU
;
Rong LIU
;
Na WANG
;
Guoqing XU
;
Zulu WANG
Author Information
1. Department of Cardiology, General Hospital of Shenyang Military Region, Shenyang 110016, China
- Publication Type:Journal Article
- Keywords:
Heart failure;
Heart rate;
Adrenergic beta-antagonists;
Ivabradine;
Cardiovascular implantable electronic device
- From:
Chinese Journal of Cardiology
2018;46(3):173-177
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To investigate the heart rate control situation of chronic heart failure (CHF) patients who received cardiovascular implantable electronic device (CIED) therapy, and to assess the heart rate control efficacy by optimized medication adjustment.
Methods:We performed a perspective study in heart failure with reduced left ventricular ejection fraction (HFrEF) patients who received CIED according to guideline recommendations, patients were enrolled from January 2012 to January 2017. Resting heart rate (RHR) recorded by electrocardiogram after 10 minutes' rest and medication usage within 1 month were recorded at baseline. RHR less than 70 beats per minute (bpm) was regarded as well controlled. β-receptor blockers and (or) ivabradine would be added in patients whose RHR were over 70 bpm. RHR after optimized medication adjustment was recorded during follow-up period.
Results:One hundred and fifty patients were included in this study with average RHR (80.6±11.9) bpm. RHR was<70 bpm in 27.3% (41/150) patients at baseline and β-receptor blockers was underused in 80.7% patients (88/109) whose RHR was>70 bpm. The overall RHR decreased to (73.1±10.4) bpm and percent of patients with RHR<70 bpm increased to 70.0% (105/150) after up-titration of β-receptor blockers compared to baseline (χ2=52.958, P<0.001). Ivabradine was added in the rest 45 patients and RHR was<70 bpm in 43 out of 45 patients after ivabradine use. The overall RHR decreased to (67.1±2.7) bpm and percent of RHR<70 bpm significantly increased to 98.7% (148/150) (χ2=44.504, P<0.001 vs. up-titration of β-receptor blockers only).
Conclusion:RHR in CHF patients who received CIED therapy is not ideally controlled in this patient cohort, individual up-titration ofβ-receptor blockers and ivabradine use may help to optimize RHR in these patients.
